New government funding will help make the boldest ideas in UK life sciences a reality.
Similar Posts
Class 4 Medicines Defect Notification: Levetiracetam Accord 100mg/ml oral solution, Accord Healthcare Limited, UK, EL(25)A/40
Accord Healthcare Limited, UK has informed the MHRA that the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SPC) do not contain all the required safety information.
Manufacturer’s Online Reporting Environment (MORE)
A digital platform designed to facilitate the reporting, monitoring, and management of medical device incidents.
MHRA approves inavolisib for the treatment of breast cancer
The MHRA has today, 26 November 2025, approved inavolisib (Itovebi) for the treatment of adults with a type of breast cancer called HR-positive
MHRA Safety Roundup: January 2026
Summary of the latest safety advice for medicines and medical device users
Research: Review of risk minimisation for disabling and potentially long-lasting/irreversible side effects associated with fluoroquinolone antibiotics
Public Assessment Report on the review of risk minimisation for fluoroquinolone antibiotics.
Field Safety Notices: 13 to 17 October 2025
List of Field Safety Notices from 13 to 17 October 2025.
